Posted on

Pure Extracts Receives Initial Purchase Order From New Brunswick

Pure Extracts Receives Initial Purchase Order From New Brunswick

Vancouver, B.C., March 10, 2022 – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, Pure Extracts Manufacturing Corp., has received an initial purchase order (PO) for its cannabis vape cartridges from Cannabis NB, the sole retailer of nonmedical cannabis in the province of New Brunswick.

The Purchase Order (PO) is for 3 SKUs of 1.0 gram Pure Pulls branded vape cartridges filled with a selection of some of the Company’s 30+ proprietary cannabis full-spectrum oil (FSO) and CBD formulations.

Pure Extracts CEO, Ben Nikolaevsky, remarked, “We are pleased to be expanding our sales and brand awareness outside of British Columbia, Alberta, Saskatchewan and Ontario into Eastern Canada. The New Brunswick PO reflects both the high-quality of our products and the consumer demand for legacy brands.”

ON BEHALF OF THE BOARD

 “Ben Nikolaevsky”

Ben Nikolaevsky
CEO and Director

About Pure Extracts (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ)

Pure Extracts Technology Corp. features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act on September 25, 2020, and its Sales Amendment on July 19, 2021. The Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020.

Find out more at https://pureextractscorp.com/

Or contact:
Pure Extracts Investor Relations
Tel: +1 604 493 2052
info@pureextractscorp.com

This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. A number of factors could cause actual events, performance or results to differ materially from what is projected in forward looking statements. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Risk Factors” in the Company’s Annual Information Form. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.

This news release contains information about potential sales revenue from supply agreements, which may be considered as disclosure of financial outlook under applicable securities laws. Such information is subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraph. Specifically, estimated sales revenue which may be derived from supply contracts has been calculated based on current wholesale prices and assume, among other things, that the Company will be able to find buyers for its products. The financial outlook contained in this news release was made by management as of the date of this news release and was provided for the purpose of providing readers with an understanding of the potential revenue which may be derived from any agreements recently entered into by the Company and are not an estimate of profitability or any other measure of financial performance. Readers are cautioned that the financial outlook contained in this document should not be used for purposes other than for which it is disclosed herein.

The CSE has neither approved nor disapproved the contents of this press release.

Posted on

Pure Extracts Technologies Corp. Closes Special Warrant Offering and Debt Settlement and Grants Options

Pure Extracts Technologies Corp. Closes Special Warrant Offering and Debt Settlement and Grants Options

Not for distribution to United States newswire services or for release, publication, distribution or dissemination, directly or indirectly, in whole or in part, in or into the United States.

VANCOUVER, British Columbia, March 08, 2022 — Pure Extracts Technologies Corp. (“Pure Extracts” or the “Company”) (CSE: PULL) (XFRA: A2QJAJ) is pleased to announce that it has completed a non-brokered private placement offering (the “Offering”) of special warrants (each, a “Special Warrant”). In connection with the Offering, the Company issued an aggregate of 5,937,001 Special Warrants at a price of $0.075 per Special Warrant, for aggregate gross proceeds of $445,275. The Company also closed its offer to settle an aggregate of $206,433in debt owed to certain creditors (the “Debt Settlement”) in exchange for units (the “Debt Units”), which Debt Units have the same terms as the units to be issued on conversion of the Special Warrants, all as further described below.

Special Warrant Offering

The Special Warrants will automatically convert to units (the “Units”) upon the earlier of the receipt for a prospectus qualifying the distribution of the Units or four months and a day from the closing date of the Offering. Each Unit will be comprised of one common share of the Company (each, a “Common Share”) and one Common Share purchase warrant (each, a “Warrant”). Each Warrant will entitle the holder to acquire one Common Share (a “Warrant Share”) at an exercise price of $0.15 per Warrant Share for a period of 24 months following the deemed exercise date of the Special Warrants.

Finder’s fees of $14,169 cash and 188,930 finder’s warrants (each a “Finder’s Warrant”) were paid and issued in conjunction with the Offering. Each Finder’s Warrant entitles the holder thereof to purchase one common share of the Company (each a “Finder’s Warrant Share”) at an exercise price of $0.15 per Finder’s Warrant Share until March 7, 2024.

All securities issued under the Offering will be subject to a statutory 4-month plus one day hold period, which expires on July 8, 2022, in accordance with applicable Canadian securities laws.

The Company intends to use net proceeds from the Offering primarily for the build-out of the Company’s Michigan, USA extraction facility and for general working capital.

The Company may elect to qualify the distribution of the Common Shares and Warrants issuable upon exercise of the Special Warrants by way of a supplement (“Prospectus Supplement”) to the Company’s short form base shelf prospectus dated March 4, 2021. The Company is under no obligation to file a Prospectus Supplement, and may elect to do so in its sole discretion. The Special Warrants and Warrants will not be listed on any stock exchange or over‐the‐counter market.

Three insiders of the Company subscribed for a total of 656,666 Special Warrants in connection with the Offering. Such participation is considered to be a “related party transaction” as defined under Multilateral Instrument 61-101 (“MI 61-101”). The transaction was exempt from the formal valuation and minority shareholder approval requirements of MI 61-101, as neither the fair market value of any securities issued to nor the consideration paid by such persons exceeded 25% of the Company’s market capitalization.

Debt Settlement

Pursuant to the Debt Settlement, the Company has issued 2,752,448 Debt Units for a total debt settlement of $206,433. Debt settled by insiders of the Company accounted for 1,035,073 Debt Units representing approximately $77,630 of the Debt Settlement. Such participation constituted a “related party transaction” within MI 61-101. The issuance to the insiders is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as the fair market value of the securities issued, or the consideration paid by such persons, did not exceed 25% of the Company’s market capitalization.

All securities issued under the Debt Settlement will be subject to a statutory 4-month plus one day hold period, which expires on July 8, 2022, in accordance with applicable Canadian securities laws.

Option Grant

The Company also announces that it has granted incentive stock options to certain directors, officers, and consultants of the Company to purchase up to 4,225,000 common shares in the capital of the Company pursuant to the Company’s stock option plan. The options are exercisable on or before March 8, 2025 at an exercise price of $0.075 per share. The grant of options is subject to regulatory approval.

The securities referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements. This news release does not constitute an offer for sale of securities for sale, nor a solicitation for offers to buy any securities.

About the Company

The Company holds a Standard Processing License under the Cannabis Act granted by Health Canada on September 25, 2020 to Pure Extracts Manufacturing Corp., the Company’s wholly-owned subsidiary. The Company is undertaking the operations of toll processing, white labelling, and developing its own private label of products incorporating its full spectrum THC and CBD based extracted oils. Additionally, the Company is presently expanding its business to include functional mushrooms extraction by working on functional mushroom extraction processes compatible with its existing infrastructure. The Company has a fully built C02 extraction facility built to European Union GMP standards, and intends to seek EU GMP certification of its operations allowing it to export its products for sale in Europe where such products are legal.

Find out more at: https://pureextractscorp.com/

Or contact:
Pure Extracts Investor Relations
Tel: +1 604 493 2052
info@pureextractscorp.com

ON BEHALF OF THE BOARD

(signed) “Ben Nikolaevsky”
Ben Nikolaevsky
CEO and Director

This information release contains certain forward-looking information, including about the proposed use of proceeds of the Offering, the filing of a Prospectus Supplement, the receipt of CSE approval and the listing of the Warrants. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Posted on

Cannabis Global Introduces 213 Solventless Labs with Focus on High Margin Cannabis Concentrates

Cannabis Global Introduces 213 Solventless Labs with Focus on High Margin Cannabis Concentrates

LOS ANGELES, CA / ACCESSWIRE / February 28, 2022 / Cannabis Global, Inc. (OTC PINK:CBGL), an innovation-oriented company investing in disruptive cannabis technologies, today announces an important enhancement to its cannabis manufacturing capabilities at its majority owned Natural Plant Extracts of California, which is located in Lynwood, a suburb of Los Angeles. The Company production capability, named 213 Solventless Labs, will specialize in producing solventless cannabis products like hash and rosin as well as solventless vape cartridges, and cannabis edibles. Operations have already begun with recent equipment installations.

“It is with great pride that we announce the production of super premium concentrates at our Lynwood facility,” CEO Arman Tabatabaei comments, “The art and science elements combined within this process allow us to produce some truly extraordinary products for the consumer cannabis markets.”

With the use of solventless concentrates, Cannabis Global is focusing on developing vertical integrations, but the ease of this process allows the Company to expand its production and manufacturing capabilities to fulfill the demand for other brands.

The Company’s solventless extraction methods use water, ice and heat to extract the desirable components from cannabis plants. This process doesn’t produce any byproducts or harmful chemicals found in other types of extracting solvents like butane, which can alter taste profile and affect the end-user’s experience with the product.

Consumers are increasingly turning to solventless products for three reasons: purity, taste and experience,” commented Arman Tabatabaei, CEO of the Company. “We do not have to remove the chemical solvents from these products as none are ever added. It’s just water, heat and pressure. Many consumers prefer the natural taste of solventless produced extracts and believe such products offer a superior user experience. We expect continued growth in the marketplace as consumers increasingly gravitate toward these high quality products.”

About Cannabis Global, Inc.

Cannabis Global, Inc. is a Los Angeles-based, fully audited and reporting Company with the U.S. Securities & Exchange Commission, trading under the stock symbol CBGL. We are an emerging force in the cannabis marketplace with a growing product and proprietary intellectual property portfolio. We are marketing and producing Comply Bag™, an innovative solution for cannabis storage, transport and tracking. Our subsidiary, Natural Plant Extract (NPE), is a Southern California licensed cannabis manufacturer and distributor which licenses our technologies to produce edibles for the cannabis marketplace. Cannabis Global has filed three non-provisional and multiple provisional patents for cannabis infusion and nanoparticle technologies and continues an active research & development program.

Forward-looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

Contact:

Arman Tabatabaei
IR@CannabisGlobalInc.com
+1 (310)-986-4929

IR Contact:

John Grosso
http://www.iconiconsulting.com/
+1 (424) 239-9521

SOURCE: Cannabis Global, Inc.

View source version on accesswire.com:
https://www.accesswire.com/690543/Cannabis-Global-Introduces-213-Solventless-Labs-with-Focus-on-High-Margin-Cannabis-Concentrates

Posted on

Medspresso Launches CBD and Functional Mushroom Single Serve Sachets

Medspresso Launches CBD and Functional Mushroom Single Serve Sachets

CAPE TOWN, SA / ACCESSWIRE / February 1, 2022 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:

Medspresso™ is pleased to announce the launch of its single-serve Super Booster Functional Mushroom Sachets and Active CBD Sachets.

Medspresso™ has sourced the highest quality raw materials and ingredients for the new lines. The products are ethically sourced, compliant to the highest food standards, and contain zero harmful additives, preservatives or psycho-active THC compounds. The amount of CBD in each product adheres to the legal limit allowed by South African law which amounts to 20 mg per person per day.

Both the CBD and Mushroom products are fully water-soluble and can be added to any hot or cold beverage in a convenient manner, or in the case of the mushroom sachet, enjoyed as a standalone tea. The new products fulfill the ever-growing demand for convenience which has become highly valued by CBD and mushroom health supplement consumers. The products are packaged in easy-to-open, one and two-gram sachets which can be stored and transported with ease.

“We are constantly looking at new and healthy ways to diversify Medspresso™’s portfolio and innovative product offerings for our customers. The introduction of the sachets allow customers a means to enjoy the incredible health benifits of CBD and functional mushrooms with such ease.” – says Michael Sachar, CEO of M2Bio Sciences Food and Beverage.

The sachets will be sold in retail-ready cartons of twenty sachets per unit. The consumer will have the choice to purchase their monthly supply immediately or buy it from select retailers and resellers in a single sachet format at the point of sale. The flexible nature of the product also sets the stage for various exciting co-branding opportunities with partnered beverage manufacturers, healthcare institutions, retailers as well as hospitality and tourism sectors.

“The new line of CBD and mushroom sachets is a step in the right direction when it comes to offering health and wellness to our ever growing customer base. We believe that the convenience of the single-serve sachets will allow new customers to try and love the product before they invest in larger quantities. The product will be available from our select resellers, online retailers as well as on the Medspresso website.” – says Jeff Robinson, CEO of M2Bio Sciences.

Mushroom Super Booster Sachets – Each sachet contains a mix of 100% natural Lion’s Mane, Turkey Tail, Cordyceps, and Reishi mushroom extract. Mushroom extracts have a much higher concentration of active compounds than the raw mushroom powder used in similar product offerings in the category. The extracts are created through a double extraction process, harnessing remarkably more bioavailability per dose, and in turn, the consumer is rewarded with a superior tasting product that is rapidly absorbed by the digestive system.

Active CBD Sachets – Each Active CBD sachet contains 20 mg of pharmaceutical grade CBD isolate, which is double the amount of similar CBD sachet offerings currently in the South African market. Medspresso prides itself on the quality and traceability of CBD used in all of its products for local and international CBD consumers. Only the purest CBD imported from Colorado, USA with legitimate certificates and licenses are used. The nano-emulsion formula used in the CBD isolate makes the CBD 100% water-soluble and easily absorbed through the gut, allowing the user to experience the full health benefits almost instantaneously. The powder itself is tasteless, odorless, and clear when mixed into the beverage, making for the perfect healthy addition without compromising the taste, color, and experience of the original beverage.

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

Publicly traded company (OTC Pink:WUHN)
Website: www.m2bio.co
E-mail: info@m2bio.co

Follow us on Twitter: https://twitter.com/Medspresso
Follow us on Facebook: https://www.facebook.com/Medspresso
Follow us on YouTube: https://www.youtube.com/channel/Medspresso
Follow us on Instagram: https://www.instagram.com/medspresso.official

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.

View source version on accesswire.com:
https://www.accesswire.com/686573/Medspresso-Launches-CBD-and-Functional-Mushroom-Single-Serve-Sachets

Posted on

Cannabis Global Provides Investor Update – Expects Current Revenue Growth Trends to Continue – Prepares Launch of New Cannabis Edible and Beverage Line

Cannabis Global Provides Investor Update – Expects Current Revenue Growth Trends to Continue – Prepares Launch of New Cannabis Edible and Beverage Line

LOS ANGELES, CA / ACCESSWIRE / January 20, 2022 / Cannabis Global, Inc. (OTC PINK:CBGL), an innovation-oriented company investing in disruptive cannabis technologies, today releases its latest update for investors and information on soon to be released new cannabis products.

Earlier this week, the Company filed its latest report for the fiscal period ended November 30, 2021. Revenues for the period totaled $569,562, which were up significantly from the year-ago quarter of November 30, 2021, which produced just $4,530. The increase in revenues was attributable to the introduction of new products, including cannabis flower, prerolls, and edibles, and significantly increased distribution revenues. Cannabis Global reported total assets at the end of the November quarter of $11.5 million compared to assets of $3.2 million at the end of the year-ago quarter.

The Company is experiencing continued firm orders from its major customers even as industry-wide cannabis sales growth within the regulated market is constrained. As a result, the Company expects revenue from the current quarter, which ends February 28, 2022, to grow from the levels reported during the November quarter.

“We are pleased with the revenue growth we reported during the November quarter and believe the growth trend is continuing into the current quarter,” commented Arman Tabatabaei, CEO of Cannabis Global. “Cannabis industry-wide issues of regulation, taxes, and black-market competition are affecting our growth, but we have taken important steps to mitigate these issues to the greatest extent possible by directing our business opportunities into areas where competition is less intense and where we have competitive advantages. We expect to maintain our focus on unique cannabis edibles, strategic distribution for a few selected highly successful customers, and on products based on solventless extracts, which we are now making inhouse, thus reducing dependence on outside partners while allowing us to capture more gross margin dollars through vertical integration.”

Cannabis Global has taken important steps to increase vertical integration of product inputs via the installation of an on-premises solventless extraction function that allows the Company to produce its own ice water hash, which Company personnel press into high-quality cannabis rosin extracts for use in the Company’s products. This vertical integration has reduced the cost of rosin extracts by more than 70%. With recently upgraded equipment, Cannabis Global has established a goal to begin marketing excess solventless extracts to other manufacturers of cannabis vape cartridges, pre-rolls, and edibles.

Cannabis Global is expecting to further increase its sales of cannabis edibles during the February quarter via the launch of several new product lines. The first of which will be marketed under the Company’s Northern Lights brand name, with the second to be produced for mass distribution throughout California for an established brand. These edibles will be based on the Company’s “No Cannabis Taste” technology, which is produced via a unique formulation developed internally by the Company. Additionally, during the current quarter, the Company plans to begin distributing cannabis-infused beverages based on all-natural, cannabis resin and rosin infusions.

Mr. Tabatabaei continued, “Over the past two years, we have invested heavily in R&D, which we believe is now paying off in the release of several unique products. Considering the mature California market in which we compete, we believe it is vital to approach the markets with new and innovative products. We are especially excited about our “No Cannabis Taste” edibles technology, which will soon be coming to market. This is the first set of products we have seen on the marketplace that exhibits zero cannabis taste. Additionally, we plan to market our beverages based on all-natural cannabis emulsions technologies developed by our research partners. We believe these products will set the bar relative to taste, quality and the list of ingredients while enabling us to yield strong ongoing margins.”

About Cannabis Global, Inc.

Cannabis Global, Inc. is a Los Angeles-based, fully audited and reporting Company with the U.S. Securities & Exchange Commission, trading under the stock symbol CBGL. We are an emerging force in the cannabis marketplace with a growing product and proprietary intellectual property portfolio. We are marketing and producing Comply Bag™, an innovative solution for cannabis storage, transport and tracking. Our subsidiary, Natural Plant Extract (NPE), is a Southern California licensed cannabis manufacturer and distributor which licenses our technologies to produce edibles for the cannabis marketplace. Cannabis Global has filed three non-provisional and multiple provisional patents for cannabis infusion and nanoparticle technologies and continues an active research & development program.

Forward-looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

Contact:

Arman Tabatabaei
IR@CannabisGlobalInc.com
+1 (310) 986-4929

IR Contact:

John Grosso
http://www.iconiconsulting.com/
+1 (424) 239-9521

SOURCE: Cannabis Global, Inc.

View source version on accesswire.com:
https://www.accesswire.com/684728/Cannabis-Global-Provides-Investor-Update–Expects-Current-Revenue-Growth-Trends-to-Continue–Prepares-Launch-of-New-Cannabis-Edible-and-Beverage-Line

Posted on

Cannabis Global Provides Investor Update – Expects Current Revenue Growth Trends to Continue – Prepares Launch of New Cannabis Edible and Beverage Line

Cannabis Global Provides Investor Update – Expects Current Revenue Growth Trends to Continue – Prepares Launch of New Cannabis Edible and Beverage Line

LOS ANGELES, CA / ACCESSWIRE / January 20, 2022 / Cannabis Global, Inc. (OTC PINK:CBGL), an innovation-oriented company investing in disruptive cannabis technologies, today releases its latest update for investors and information on soon to be released new cannabis products.

Earlier this week, the Company filed its latest report for the fiscal period ended November 30, 2021. Revenues for the period totaled $569,562, which were up significantly from the year-ago quarter of November 30, 2021, which produced just $4,530. The increase in revenues was attributable to the introduction of new products, including cannabis flower, prerolls, and edibles, and significantly increased distribution revenues. Cannabis Global reported total assets at the end of the November quarter of $11.5 million compared to assets of $3.2 million at the end of the year-ago quarter.

The Company is experiencing continued firm orders from its major customers even as industry-wide cannabis sales growth within the regulated market is constrained. As a result, the Company expects revenue from the current quarter, which ends February 28, 2022, to grow from the levels reported during the November quarter.

“We are pleased with the revenue growth we reported during the November quarter and believe the growth trend is continuing into the current quarter,” commented Arman Tabatabaei, CEO of Cannabis Global. “Cannabis industry-wide issues of regulation, taxes, and black-market competition are affecting our growth, but we have taken important steps to mitigate these issues to the greatest extent possible by directing our business opportunities into areas where competition is less intense and where we have competitive advantages. We expect to maintain our focus on unique cannabis edibles, strategic distribution for a few selected highly successful customers, and on products based on solventless extracts, which we are now making inhouse, thus reducing dependence on outside partners while allowing us to capture more gross margin dollars through vertical integration.”

Cannabis Global has taken important steps to increase vertical integration of product inputs via the installation of an on-premises solventless extraction function that allows the Company to produce its own ice water hash, which Company personnel press into high-quality cannabis rosin extracts for use in the Company’s products. This vertical integration has reduced the cost of rosin extracts by more than 70%. With recently upgraded equipment, Cannabis Global has established a goal to begin marketing excess solventless extracts to other manufacturers of cannabis vape cartridges, pre-rolls, and edibles.

Cannabis Global is expecting to further increase its sales of cannabis edibles during the February quarter via the launch of several new product lines. The first of which will be marketed under the Company’s Northern Lights brand name, with the second to be produced for mass distribution throughout California for an established brand. These edibles will be based on the Company’s “No Cannabis Taste” technology, which is produced via a unique formulation developed internally by the Company. Additionally, during the current quarter, the Company plans to begin distributing cannabis-infused beverages based on all-natural, cannabis resin and rosin infusions.

Mr. Tabatabaei continued, “Over the past two years, we have invested heavily in R&D, which we believe is now paying off in the release of several unique products. Considering the mature California market in which we compete, we believe it is vital to approach the markets with new and innovative products. We are especially excited about our “No Cannabis Taste” edibles technology, which will soon be coming to market. This is the first set of products we have seen on the marketplace that exhibits zero cannabis taste. Additionally, we plan to market our beverages based on all-natural cannabis emulsions technologies developed by our research partners. We believe these products will set the bar relative to taste, quality and the list of ingredients while enabling us to yield strong ongoing margins.”

About Cannabis Global, Inc.

Cannabis Global, Inc. is a Los Angeles-based, fully audited and reporting Company with the U.S. Securities & Exchange Commission, trading under the stock symbol CBGL. We are an emerging force in the cannabis marketplace with a growing product and proprietary intellectual property portfolio. We are marketing and producing Comply Bag™, an innovative solution for cannabis storage, transport and tracking. Our subsidiary, Natural Plant Extract (NPE), is a Southern California licensed cannabis manufacturer and distributor which licenses our technologies to produce edibles for the cannabis marketplace. Cannabis Global has filed three non-provisional and multiple provisional patents for cannabis infusion and nanoparticle technologies and continues an active research & development program.

Forward-looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

Contact:

Arman Tabatabaei
IR@CannabisGlobalInc.com
+1 (310) 986-4929

IR Contact:

John Grosso
http://www.iconiconsulting.com/
+1 (424) 239-9521

SOURCE: Cannabis Global, Inc.

View source version on accesswire.com:
https://www.accesswire.com/684728/Cannabis-Global-Provides-Investor-Update–Expects-Current-Revenue-Growth-Trends-to-Continue–Prepares-Launch-of-New-Cannabis-Edible-and-Beverage-Line

Posted on

Pure Extracts Signs White Label Agreement With West Coast Licensed Producer

Pure Extracts Signs White Label Agreement With West Coast Licensed Producer

Vancouver, B.C., January 12, 2022 – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, Pure Extracts Manufacturing Corp., has signed a custom manufacturing/white label agreement with a West Coast Licensed Producer to launch a line of vape products.

The agreement calls for the extraction of premium cannabis supplied by the LP and the subsequent formulation into high quality, full-spectrum oil (FSO) 1 gram vape cartridges. These products will be created by collaboration between the two companies with a reliance on Pure Extracts’ 30+ proprietary formulations and its optimized vape hardware. Pure Extracts will be providing co-manufacturing extraction services. The initial order has an approximate retail sales value of $525,000

This science-based LP has extensive experience in the growing medical-grade cannabis for patients and are now excited to apply their experience towards producing first-rate cannabis for the legalized adult-use market in Canada. Their meticulous standards are used at every step of product development, from growing and processing to R&D.

Pure Extracts CEO, Ben Nikolaevsky, remarked, “We are excited about launching a white label product with our new customer, as they are focused on creating state-of-the-art products utilizing cannabis they grow themselves. With the addition of this customer and the increased capacity and flexibility our new cosolvent injection system provides, we have begun to execute our strategy with high quality producers and branding specialists to get their white label products into the provincial retailers and drive up to $3 million of annual revenue from this vertical.”

ON BEHALF OF THE BOARD

“Ben Nikolaevsky”
Ben Nikolaevsky
CEO and Director

About Pure Extracts (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ)

Pure Extracts Technology Corp. features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act on September 25, 2020, and its Sales Amendment on July 19, 2021. The Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020.

Find out more at https://pureextractscorp.com/

Or contact:

Pure Extracts Investor Relations
Tel: +1 604 493 2052
info@pureextractscorp.com    

This news release contains forward-looking statements relating to the future operations of Pure Extracts,

and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. A number of factors could cause actual events, performance or results to differ materially from what is projected in forward looking statements. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Risk Factors” in the Company’s Annual Information Form. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.

This news release contains information about potential sales revenue from supply agreements, which may be considered as disclosure of financial outlook under applicable securities laws. Such information is subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraph. Specifically, estimated sales revenue which may be derived from supply contracts has been calculated based on current wholesale prices and assume, among other things, that the Company will be able to find buyers for its products. The financial outlook contained in this news release was made by management as of the date of this news release and was provided for the purpose of providing readers with an understanding of the potential revenue which may be derived from any agreements recently entered into by the Company, and are not an estimate of profitability or any other measure of financial performance. Readers are cautioned that the financial outlook contained in this document should not be used for purposes other than for which it is disclosed herein.

The CSE has neither approved nor disapproved the contents of this press release.

Posted on

Cannabis Global Reports Significantly Increased Revenues for the Fiscal Year End – Files Annual Report

Cannabis Global Reports Significantly Increased Revenues for the Fiscal Year End – Files Annual Report

LOS ANGELES, CA / ACCESSWIRE / December 15, 2021 / Cannabis Global, Inc. (OTC PINK:CBGL), an innovation-oriented company investing in disruptive cannabis technologies, today announced the filing of its annual report for the fiscal year ended August 31, 2021. Revenues for the fiscal year grew to just over $1.6 million, compared to approximately $27,000 for the previous fiscal year. Growth was attributed to increased sales and distribution of cannabis products across a broad array of product lines, including cannabis flower, edibles, and concentrates.

“We are pleased with the strong growth of our distribution and manufacturing businesses via Northern Lights Distribution and Natural Plant Extract of California, respectively,” commented CEO Arman Tabatabaei. “The customers generating our growth are ordering consistently into this current fiscal year and in some cases are expanding orders and revenues with us. With strong revenue growth and pending new product introductions we remain confident moving into calendar 2022. Our major emphasis moving forward will be to improve profitability especially relating to our high cost of capital to better ensure our bottom line matches the strength of our revenue growth.”

CBGL has recently announced the addition of several new product categories, including solventless extracts, infused cannabis pre-rolls and innovative categories of cannabis edibles, which are expected to be released soon after the first of the new year.

Mr. Tabatabaei continued, “While this past fiscal year was a year of acquisition, product development and of positioning our products and distribution efforts into an increasingly competitive California cannabis market, we anticipate this current fiscal year being one of emphasis on profitability, new product introductions and full utilization of our suburban Los Angeles manufacturing and distribution facilities.”

About Cannabis Global, Inc.

Cannabis Global, Inc. is a Los Angeles-based, fully audited and reporting Company with the U.S. Securities & Exchange Commission, trading under the stock symbol CBGL. We are an emerging force in the cannabis marketplace with a growing product and proprietary intellectual property portfolio. We are marketing and producing Comply Bag™, an innovative solution for cannabis storage, transport and tracking. Our subsidiary, Natural Plant Extract (NPE), is a Southern California licensed cannabis manufacturer and distributor which licenses our technologies to produce edibles for the cannabis marketplace. Cannabis Global has filed three non-provisional and multiple provisional patents for cannabis infusion and nanoparticle technologies and continues an active research & development program.

Forward-looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

Contact:
Arman Tabatabaei
IR@CannabisGlobalInc.com
+1 (310) 986-4929

IR Contact:
John Grosso
http://www.iconiconsulting.com/
+1 (424) 239-9521

SOURCE: Cannabis Global, Inc.

View source version on accesswire.com:
https://www.accesswire.com/677721/Cannabis-Global-Reports-Significantly-Increased-Revenues-for-the-Fiscal-Year-End–Files-Annual-Report

Posted on

Pure Extracts’ and Golden Harvests’ Joint Venture Receives Medical Prequalification Status Letter in Michigan

Pure Extracts’ and Golden Harvests’ Joint Venture Receives Medical Prequalification Status Letter in Michigan

Vancouver, British Columbia and Medford, Oregon, December 15, 2021 – Pure Extracts Technologies Corp. (“Pure Extracts”) (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) and Grown Rogue International Inc.’s (“Grown Rogue”) (CSE: GRIN) (OTC: GRUSF) partner, Golden Harvests, LLC, are pleased to announce that their Michigan extraction joint venture (JV) company, Pure Grown Extracts, LLC (“Pure Grown Extracts”), received its medical Prequalification Status Letter from the Michigan Marijuana Regulatory Agency (MRA) on November 23, 2021.

This letter was issued pursuant to the licensing provisions of the Medical Marihuana Facilities Licensing Act (MMFLA) and associated rules and allows Pure Grown Extracts to submit a facility license application 60 days prior to when the facility will be ready for inspection by the MRA.

“We are excited to be ramping this project up with Golden Harvests in Michigan, where cannabis sales continue to set records with monthly sales up over 50% from a year ago,” said Ben Nikolaevsky, CEO of Pure Extracts. “Establishing Pure Extracts’ brands in Michigan, an important state in the large US cannabis market, is a critical milestone for our company.”

The goal of the JV is to bring Pure Extracts’ portfolio of products to Michigan and to expand Grown Rogue’s product offering. Pure Extracts is a plant-based extraction company focused on cannabis and hemp based out of British Columbia, Canada and will provide a mix of equipment, cash, and extraction expertise to the venture, which will allow the partners to rapidly scale-up to meet the rising demand for processed products throughout the state. Grown Rogue is a multi-state operating (MSO) cannabis company with operations and assets in Oregon and in Michigan where they are already doing business with over 100 dispensaries throughout the state.

“We are pleased to have received such a timely response from the MRA on our medical cannabis processing application and look forward to finishing the construction and getting additional award-winning products into the Michigan market to supplement our leading flower brand already established in the state,” said Obie Strickler, CEO of Grown Rogue.

The joint venture plans to build-out existing space in the 80,000 sq. ft. facility in Bay City where it has the ability to produce Pure Extracts’ branded concentrates, cartridges, edibles and tinctures as well as a suite of Grown Rogue products capturing the west coast innovation they are known for.

About Grown Rogue

Grown Rogue International (CSE: GRIN | OTC: GRUSF) is a vertically integrated, multi-state Cannabis family of brands on a mission to inspire consumers to “enhance experiences” through cannabis. We have combined an expert management team, award winning grow team, state of the art indoor and outdoor manufacturing facilities, and consumer insight-based product categorization, to create innovative products thoughtfully curated from “seed to experience.”  The Grown Rogue family of products include sungrown and indoor premium flower, along with nitro sealed indoor and sungrown pre-rolls and jars.

About Pure Extracts

Pure Extracts Technology Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. Health Canada, under the Cannabis Act, granted Pure Extracts its Standard Processing License on September 25, 2020, and its Sales Amendment on July 19, 2021. The company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020.

FORWARD-LOOKING STATEMENTS

This press release contains statements which constitute “forward‐looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Grown Rogue and Pure Extracts       (“the Companies”) with respect to future business activities. Forward‐ looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions and include information regarding: (i) statements regarding the future direction of the Companies (ii) the ability of the Company to successfully achieve its business and financial objectives, (iii) plans for expansion of the Companies into Michigan and securing applicable regulatory approvals, and (iv) expectations for other economic, business, and/or competitive factors. Investors are cautioned that forward‐looking information is not based on historical facts but instead reflect the Companies’ management’s expectations, estimates or projections concerning the business of the Companies’ future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Companies believe that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the combined company. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; and in particular in the ability of the Companies to raise debt and equity capital in the amounts and at the costs that it expects; adverse changes in the public perception of cannabis; decreases in the prevailing prices for cannabis and cannabis products in the markets that the Companies operate in; adverse changes in applicable laws; or adverse changes in the application or enforcement of current laws; compliance with extensive government regulation and related costs, and other risks described in the Companies’ public disclosure documents filed on www.sedar.com.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Companies have attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Companies do not intend, and do not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law.

For further information on Grown Rogue International please visit www.grownrogue.com or contact:

Obie Strickler
Chief Executive Officer
obie@grownrogue.com

Investor Relations Desk Inquiries
invest@grownrogue.com
(458) 226-2100

For further information on Pure Extracts please visit www.pureextractscorp.com/ or contact:
Pure Extracts Investor Relations
Tel: +1 604 493 2052
info@pureextractscorp.com

SAFE HARBOR STATEMENT

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Companies, its directors or its officers with respect to, among other things: (i) the Company’s financing plans; (ii) trends affecting the Companies’ financial condition or results of operations; (iii) the Companies’ growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Companies’ ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors including the risk disclosed in Grown Rogue’s Form 20-F and 6-K filings with the Securities and Exchange Commission.

STATEMENT REGARDING UNITED STATES REGULATORY FRAMEWORK FOR CANNABIS

Pursuant to Pure Extracts’ joint venture with Golden Harvests, LLC, Pure Extracts expects to derive revenues from the cannabis industry in the State of Michigan in the United States, which industry is illegal under United States federal law. The joint venture is expected to be directly or indirectly engaged in the manufacture, possession, use, sale and distribution of cannabis in the medical and/or adult-use cannabis marketplace in the State of Michigan.

The United States federal government regulates drugs through the Controlled Substances Act (21 U.S.C. § 811) (the “CSA”), which places controlled substances, including cannabis, in a schedule. Cannabis is classified as a Schedule I drug. Under United States federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of accepted safety for the use of the drug under medical supervision. The United States Food and Drug Administration has not approved cannabis as a safe and effective drug for any indication.

In the United States, cannabis is largely regulated at the state level. State laws regulating cannabis are in direct conflict with the federal Controlled Substances Act, which makes cannabis use and possession federally illegal. Although certain states authorize medical and/or adult-use cannabis production and distribution by licensed or registered entities, under United States federal law, the possession, use, cultivation, and transfer of cannabis and any cannabis-related drug paraphernalia is illegal, and any such acts are criminal acts under federal law. The Supremacy Clause of the United States Constitution establishes that the United States Constitution and federal laws made pursuant to it are paramount and in case of conflict between federal and state law, the federal law shall apply.

There is no guarantee that state laws legalizing and regulating the sale and use of cannabis will not be repealed or overturned, or that local governmental authorities will not limit the applicability of state laws within their respective jurisdictions. Unless and until the United States Congress amends the CSA with respect to medical and/or adult-use cannabis (and as to the timing or scope of any such potential amendments there can be no assurance), there is a risk that U.S. federal authorities may enforce current U.S. federal law. If the U.S. federal government begins to enforce U.S. federal laws relating to cannabis in states where the sale and use of cannabis is currently legal, or if existing applicable state laws are repealed or curtailed, Pure Extracts’ business, results of operations, financial condition and prospects would be materially adversely affected. For these reasons, Pure Extracts’ operations in the United States cannabis market (through the joint venture) may subject Pure Extracts to heightened scrutiny by regulators, stock exchanges, clearing agencies and other Canadian and U.S. authorities and is subject to a number of risks, including those risks that are described in the Companies’ public filings profile on SEDAR at www.sedar.com.

To Pure Extracts’ knowledge, no statement has been made by federal authorities or prosecutors regarding the risk of enforcement action with respect to state-sanctioned marijuana activities in the state of Michigan.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Posted on

Pure Extracts Ships Repeat Order of 1-gram Vapes

Pure Extracts Ships Repeat Order of 1-gram Vapes

Vancouver, B.C., December 2, 2021 – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, Pure Extracts Manufacturing Corp., has shipped another order of vape carts via its distribution partner, Abba Medix, to the British Columbia Liquor Distribution Branch (LDB), the sole wholesale distributor of non-medical cannabis in the province.

These 1.0 gram vapes are selling out on-schedule and the Company has consistently been able to fulfill regular, follow-on purchase orders (POs) on time and in the quantities requested by the LDB.

The Pure Pulls branded vape cartridges were filled with a selection of some of the Company’s 30+ proprietary cannabis full-spectrum oil (FSO) formulations including Grand Daddy Purple and GSC.

Pure Extracts CEO, Ben Nikolaevsky, remarked, “We are pleased to be expanding our sales and brand awareness in our home province of British Columbia. The repeat orders we have shipped to the LDB underscore the high-quality of our products and the reliability of our manufacturing processes.”

ON BEHALF OF THE BOARD

“Ben Nikolaevsky”
Ben Nikolaevsky
CEO and Director

About Pure Extracts (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ)

Pure Extracts Technology Corp. features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act on September 25, 2020, and its Sales Amendment on July 19, 2021. The Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020.

Find out more at https://pureextractscorp.com/

Or contact:

Pure Extracts Investor Relations
Tel: +1 604 493 2052
info@pureextractscorp.com    

ON BEHALF OF THE BOARD

“Ben Nikolaevsky”
Ben Nikolaevsky
CEO and Director

This news release contains forward-looking statements relating to the future operations of Pure Extracts,

and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. A number of factors could cause actual events, performance or results to differ materially from what is projected in forward looking statements. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Risk Factors” in the Company’s Annual Information Form. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.

This news release contains information about potential sales revenue from supply agreements, which may be considered as disclosure of financial outlook under applicable securities laws. Such information is subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraph. Specifically, estimated sales revenue which may be derived from supply contracts has been calculated based on current wholesale prices and assume, among other things, that the Company will be able to find buyers for its products. The financial outlook contained in this news release was made by management as of the date of this news release and was provided for the purpose of providing readers with an understanding of the potential revenue which may be derived from any agreements recently entered into by the Company and are not an estimate of profitability or any other measure of financial performance. Readers are cautioned that the financial outlook contained in this document should not be used for purposes other than for which it is disclosed herein.

The CSE has neither approved nor disapproved the contents of this press release.